CY1121696T1 - Φαρμακευτικη συνθεση παρατεταμενης απελευθερωσης της τριμεταζιδινης - Google Patents
Φαρμακευτικη συνθεση παρατεταμενης απελευθερωσης της τριμεταζιδινηςInfo
- Publication number
- CY1121696T1 CY1121696T1 CY20191100621T CY191100621T CY1121696T1 CY 1121696 T1 CY1121696 T1 CY 1121696T1 CY 20191100621 T CY20191100621 T CY 20191100621T CY 191100621 T CY191100621 T CY 191100621T CY 1121696 T1 CY1121696 T1 CY 1121696T1
- Authority
- CY
- Cyprus
- Prior art keywords
- trimetazidine
- pharmaceutical composition
- extended release
- release pharmaceutical
- aggregation
- Prior art date
Links
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001177 trimetazidine Drugs 0.000 title abstract 3
- 238000013265 extended release Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002744 anti-aggregatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008384 inner phase Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Σύνθεση παρατεταμένης απελευθέρωσης της τριμεταζιδίνης, στην οποία η εσωτερική φάση περιλαμβάνει την τριμεταζιδίνη και η εξωτερική στοιβάδα περιλαμβάνει ένα επιβραδυντικό και ένα αντι-συσσωματικό.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1200322A FR2986431B1 (fr) | 2012-02-03 | 2012-02-03 | Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121696T1 true CY1121696T1 (el) | 2020-07-31 |
Family
ID=47504206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100621T CY1121696T1 (el) | 2012-02-03 | 2019-06-18 | Φαρμακευτικη συνθεση παρατεταμενης απελευθερωσης της τριμεταζιδινης |
Country Status (47)
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2675002T3 (es) * | 2014-04-08 | 2018-07-05 | Dow Global Technologies Llc | Dispersión que comprende un éter de celulosa esterificado |
US20180140599A1 (en) * | 2016-11-21 | 2018-05-24 | Saghmos Therapeutics, Inc. | Prevention and/or treatment of contrast-induced acute kidney injury |
CN109316455B (zh) * | 2017-07-31 | 2021-05-25 | 北京福元医药股份有限公司 | 一种***美他嗪缓释片 |
CN110237053A (zh) * | 2019-07-26 | 2019-09-17 | 湖北欣泽霏药业有限公司 | 一种***美他嗪缓释微丸及其制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL270408A (el) * | 1960-10-20 | |||
FR2490963B1 (fr) | 1980-09-30 | 1986-04-18 | Science Union & Cie | Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine |
JPH04169522A (ja) * | 1990-11-01 | 1992-06-17 | Shin Etsu Chem Co Ltd | 徐放性錠剤およびその製造方法 |
FR2717687B1 (fr) * | 1994-03-24 | 1996-06-14 | Adir | Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale. |
FR2802424B1 (fr) * | 1999-12-17 | 2002-02-15 | Adir | Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale |
DE60042972D1 (de) * | 2000-10-05 | 2009-10-29 | Usv Ltd | Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung |
EP1448173A2 (en) * | 2001-11-21 | 2004-08-25 | Themis Laboratories Private Limited | A process for manufacture of a sustained release pharmaceutical composition containing microbeads of trimetazidine dihydrochloride |
RU2281772C1 (ru) * | 2005-02-14 | 2006-08-20 | Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" | Лекарственная форма, обладающая антиангинальным действием, и способ ее изготовления |
WO2007133583A2 (en) * | 2006-05-09 | 2007-11-22 | Mallinckrodt Inc. | Zero-order modified release solid dosage forms |
CN100571703C (zh) * | 2006-12-20 | 2009-12-23 | 山东省医药工业研究所 | 曲美他嗪缓释微丸及其制备方法 |
CN101854929A (zh) * | 2007-11-09 | 2010-10-06 | 田边三菱制药株式会社 | 新型制剂 |
RU2362548C1 (ru) * | 2007-11-20 | 2009-07-27 | Закрытое Акционерное Общество "Канонфарма Продакшн" | Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения |
US20110300209A1 (en) * | 2009-01-20 | 2011-12-08 | Micro Labs Limited | Modified release solid pharmaceutical compositions of trimetazidine and process thereof |
WO2010086868A1 (en) * | 2009-01-30 | 2010-08-05 | Lupin Limited | Pharmaceutical compositions of trimetazidine |
EP2408437A1 (en) * | 2009-03-18 | 2012-01-25 | Evonik Röhm GmbH | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients |
US20110274751A1 (en) * | 2010-05-04 | 2011-11-10 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Trimetazidine formulation with different release profiles |
CN102133195A (zh) * | 2011-03-17 | 2011-07-27 | 王国栋 | ***美他嗪的缓控释微丸及其制备方法 |
-
2012
- 2012-02-03 FR FR1200322A patent/FR2986431B1/fr not_active Expired - Fee Related
- 2012-05-09 RO ROA201200317A patent/RO128004A3/ro unknown
-
2013
- 2013-01-23 PH PH12013000031A patent/PH12013000031B1/en unknown
- 2013-01-24 PE PE2013000132A patent/PE20131119A1/es active IP Right Grant
- 2013-01-25 SG SG2013006119A patent/SG192386A1/en unknown
- 2013-01-25 UY UY0001034595A patent/UY34595A/es not_active Application Discontinuation
- 2013-01-27 JO JOP/2013/0029A patent/JO3505B1/ar active
- 2013-01-28 MX MX2013001118A patent/MX363302B/es unknown
- 2013-01-28 CR CR20130037A patent/CR20130037A/es unknown
- 2013-01-28 AP AP2013006693A patent/AP2013006693A0/xx unknown
- 2013-01-28 CA CA2805471A patent/CA2805471C/fr active Active
- 2013-01-28 CU CU20130016A patent/CU24157B1/es active IP Right Grant
- 2013-01-29 GE GEAP201312984A patent/GEP20156342B/en unknown
- 2013-01-29 US US13/753,313 patent/US10117838B2/en active Active
- 2013-01-30 SV SV2013004396A patent/SV2013004396A/es unknown
- 2013-01-30 AU AU2013200481A patent/AU2013200481B2/en active Active
- 2013-01-30 IL IL224495A patent/IL224495B/en active IP Right Grant
- 2013-01-30 HR HRP20130082AA patent/HRP20130082A2/hr not_active Application Discontinuation
- 2013-01-31 MY MYPI2013700179A patent/MY162599A/en unknown
- 2013-01-31 UA UAA201301194A patent/UA118742C2/uk unknown
- 2013-01-31 CO CO13017769A patent/CO6720159A1/es unknown
- 2013-01-31 DO DO2013000024A patent/DOP2013000024A/es unknown
- 2013-01-31 RS RS20130034A patent/RS20130034A1/en unknown
- 2013-01-31 GT GT201300032A patent/GT201300032A/es unknown
- 2013-01-31 NI NI201300014A patent/NI201300014A/es unknown
- 2013-02-01 CL CL2013000336A patent/CL2013000336A1/es unknown
- 2013-02-01 KR KR1020130011816A patent/KR20130090365A/ko active Application Filing
- 2013-02-01 RU RU2013104252A patent/RU2621128C2/ru active
- 2013-02-01 DK DK13153638.5T patent/DK2623096T3/da active
- 2013-02-01 JP JP2013018173A patent/JP6338818B2/ja active Active
- 2013-02-01 ES ES13153638T patent/ES2735053T3/es active Active
- 2013-02-01 SI SI201331428T patent/SI2623096T1/sl unknown
- 2013-02-01 EP EP13153638.5A patent/EP2623096B1/fr active Active
- 2013-02-01 TW TW102104128A patent/TWI508755B/zh active
- 2013-02-01 WO PCT/FR2013/050213 patent/WO2013114053A2/fr active Application Filing
- 2013-02-01 HU HUE13153638A patent/HUE043942T2/hu unknown
- 2013-02-01 EC ECSP13012415 patent/ECSP13012415A/es unknown
- 2013-02-01 LT LTEP13153638.5T patent/LT2623096T/lt unknown
- 2013-02-01 AR ARP130100294A patent/AR089861A1/es not_active Application Discontinuation
- 2013-02-01 BR BR102013002524A patent/BR102013002524B1/pt active IP Right Grant
- 2013-02-01 PT PT13153638T patent/PT2623096T/pt unknown
- 2013-02-01 EA EA201300079A patent/EA030227B1/ru unknown
- 2013-02-01 RS RS20190598A patent/RS58752B1/sr unknown
- 2013-02-01 PL PL13153638T patent/PL2623096T3/pl unknown
- 2013-02-01 TR TR2019/06390T patent/TR201906390T4/tr unknown
- 2013-02-03 MD MD20130005A patent/MD4622C1/ro active IP Right Grant
- 2013-02-04 CN CN201611094283.6A patent/CN106924221A/zh active Pending
- 2013-02-04 CN CN2013100434345A patent/CN103239425A/zh active Pending
-
2015
- 2015-08-26 KR KR1020150120470A patent/KR101918211B1/ko active IP Right Grant
-
2019
- 2019-06-14 HR HRP20191072 patent/HRP20191072T1/hr unknown
- 2019-06-18 CY CY20191100621T patent/CY1121696T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
CY1118001T1 (el) | Νεες ctla4-ig προσκολλητινες | |
CY1122796T1 (el) | Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων | |
CL2014003136A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos. | |
CY1121696T1 (el) | Φαρμακευτικη συνθεση παρατεταμενης απελευθερωσης της τριμεταζιδινης | |
CR20150049A (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
CR20150048A (es) | Anticuerpos e inmunoconjugados anti-cd22 | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
BR112013024267A2 (pt) | compostos tricíclicos fundidos substituídos, composições e aplicações medicinais dos mesmos. | |
CR20140529A (es) | Anticuerpos e inmunoconjugados contra ly6e y métodos de uso | |
DK3066085T3 (da) | Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor | |
BR112016000489A2 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
DK3030262T3 (da) | Kombineret farmaceutisk sammensætning | |
BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
BR112015003259A2 (pt) | composto, composição farmacêutica, e, composição de vacina. | |
AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
BR112015029665A2 (pt) | arquitetura de montagem que emprega suporte orgânico para produção de montagem compacta e aprimorada. | |
BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
BR112015002824A2 (pt) | composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação. | |
IT1398070B1 (it) | Proiettore da palcoscenico. | |
BR112015010797A2 (pt) | compostos aniônicos substituídos, e, composição farmacêutica | |
CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
CO6761388A2 (es) | Composiciones pharmaceuticas que comprenden alisporivir | |
BR112014032501A2 (pt) | composto, e, composição farmacêutica. |